You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK):復宏漢霖擬科創板上市拓寬融資渠道
格隆匯 03-30 22:52

格隆匯3月30日丨復星醫藥(02196.HK)、復星國際(00656.HK)公佈,復星醫藥董事會及復星國際董事會已分別於2020年3月30日審議並批准有關建議復宏漢霖科創板上市的議案。

在假設根據建議復宏漢霖上市的最大發行量(並假設超額配售權獲悉數行使)發行A股股份的情況下,預計緊隨建議復宏漢霖上市完成後,復星醫藥及復星國際將繼續間接持有復宏漢霖不低於其已發行股本的約41.42%的股份,復宏漢霖仍為復星醫藥及復星國際的附屬公司且繼續在復星醫藥集團及復星國際集團合併報表範圍內。

復宏漢霖擬公開發行股票數量不高於建議復宏漢霖上市完成後其總股本的20%,且不低於發行後其總股本的10%,具體以中國證監會實際註冊A股數量為準。根據復宏漢霖的實際情況,本次發行的募集資金扣除發行費用後,初步考慮用於生物類似藥及創新藥研發項目、生物醫藥產業化基地項目以及補充營運資金。

公司稱,儘管完成建議復宏漢霖上市將導致復星醫藥及復星國際持有復宏漢霖的權益被攤薄,但是通過科創板上市,將有利於復宏漢霖拓寬融資渠道,直接對接境內資本市場,實現獨立融資,支持單克隆抗體藥物相關業務做大做強,進而有助於提升復星醫藥集團及復星國際集團未來的整體盈利水準。與此同時,通過科創板上市,有利於實現價值發現和價值創造,有利於強化復星醫藥集團和復星國際集團的資產流動性、提高償債能力、降低復星醫藥集團和復星國際集團的運行風險。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account